A Pharmaco-epidemiological Study of Short Patients Born Small for Gestational Age (SGA), Treated With Saizen® (Recombinant Somatropin)

2014-07-23 21:09:54 | BioPortfolio


This one-arm, multi-centric, non-randomized, observational, open label, prospective study was designed to study short subjects born SGA, by pediatricians, endocrinologists or physicians in private, mixed private and hospital practice treated with Saizen.


The term "small for gestational age" (SGA) is a pathological medical condition known since about two decades supported by two consensus conferences of 2001. It inhibits the height and/or weight of the child at birth without prejudging the mechanisms that alter these. This study will be carried out by hospital pediatricians, endocrinologists or physicians in private, mixed private and hospital practice in metropolitan France. Subjects will be monitored by doctors in accordance with the normal scope of follow-up of pathology until their final growth and until they reach adult height and/or until the treatment is discontinued. The participating doctors will include all the short SGA subjects coming for consultation or the follow-up (for less than 12 months) of their GH treatment in this study. The inclusions will take place over a period of 12 months.


Primary objective:

- To describe the characteristics of short children born SGA (SGA subjects) treated with Saizen

Secondary objectives:

- To describe the terms and conditions for the prescription of Saizen in terms of dosage, duration of treatment, reason for discontinuation and compliance

- To describe the effects of Saizen on growth and final height

- To describe the tolerance of Saizen For each subject and during each visit, the participating doctor will complete an electronic data collection form.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Infant, Small for Gestational Age


recombinant somatropin


Merck Serono Investigational Site
Aix en Provence




Merck KGaA

Results (where available)

View Results


Published on BioPortfolio: 2014-07-23T21:09:54-0400

Clinical Trials [860 Associated Clinical Trials listed on BioPortfolio]

Safety and Efficacy of Somatropin (rhGH) in Short Children Born Small for Gestational Age (SGA)

This study is performed to investigate the long-term safety, in particular the diabetogenic potential and immunogenicity of rhGH therapy in short children born small for gestational age (S...

Special Investigation Of Genotropin Long Follow-Up For Patients With A Small For Gestational Age (SGA)

The objective of this surveillance is to collect Safety and Effectiveness information for Long term Use of Somatropin for Patients with a Small for Gestational Age (SGA).

Long Term Study of Genotropin (Somatropin) for Short Children Born Small for Gestational Age (SGA)

To assess the long-term safety of Genotropin(somatropin) on Small for Gestational Age (SGA) without epiphyseal closing.

Growth Hormone Treatment in Short Children Born Small for Gestational Age

Comparison of 2 different doses of human growth hormone treatment on change in height after 1 and 2 years of treatment.

A Study of Recombinant Human Growth Hormone Injection(JINTOPIN AQ)for Short Children With Small for SGA

To preliminary assess the efficacy and safety of recombinant human growth hormone injection on the treatment of small for gestational age (SGA), and determine the best dose.

PubMed Articles [6837 Associated PubMed Articles listed on BioPortfolio]

Intrapartum Fetal Heart Rate Tracing Among Small-for-Gestational Age Compared With Appropriate-for-Gestational-Age Neonates.

To compare fetal heart rate (FHR) patterns during the last hour of labor between small-for-gestational-age (SGA; birth weight less than the 10th percentile for gestational age) and appropriate-for-ges...

Alteration of the colostrum whey proteome in mothers with gestational hypothyroidism.

Gestational hypothyroidism (G-HypoT) is one of the most common thyroid diseases in pregnant women. Human milk, which closely links the mother with infant, is an important factor to the infant health. ...

Maternal seafood intake and the risk of small for gestational age newborns: a case-control study in Spanish women.

To investigate the relationship between seafood consumption during pregnancy and the risk of delivering a small for gestational age (SGA) newborn.

Bronchopulmonary dysplasia in neonates born to mothers with preeclampsia: Impact of small for gestational age.

Small for gestational age and preeclampsia have both been described as risk factors for bronchopulmonary dysplasia in preterm neonates, but their respective role in the occurrence of bronchopulmonary ...

Maternal short stature and under-weight status are independent risk factors for preterm birth and small for gestational age in rural Bangladesh.

To estimate the risks of term-small for gestational age (SGA), preterm-appropriate for gestational age (AGA), and preterm SGA associated with maternal height and body mass index (BMI) and to calculate...

Medical and Biotech [MESH] Definitions

An infant having a birth weight lower than expected for its gestational age.

The event that a FETUS is born alive with heartbeats or RESPIRATION regardless of GESTATIONAL AGE. Such liveborn is called a newborn infant (INFANT, NEWBORN).

An infant whose weight at birth is less than 1000 grams (2.2 lbs), regardless of gestational age.

An infant whose weight at birth is less than 1500 grams (3.3 lbs), regardless of gestational age.

The death of a FETUS of GESTATIONAL AGE 28 weeks or more, or the death of a live-born INFANT less than 28 days of age.

More From BioPortfolio on "A Pharmaco-epidemiological Study of Short Patients Born Small for Gestational Age (SGA), Treated With Saizen® (Recombinant Somatropin)"

Quick Search


Relevant Topics

Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Searches Linking to this Trial